

 PRESS RELEASE

PARIS - FRANCE / SAN FRANCISCO - USA - OCTOBER 29, 2020

## Lesaffre and Recombia Biosciences to Advance Innovative Gene Editing technology through a strategic partnership.

Recombia Biosciences announces the launch of operations in Brisbane, California. The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development.

### A strong commitment to innovation

With its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in parallel, combined with laboratory automation, is expected to exponentially accelerate development of projects in the areas of health, the environment, and energy. The partnership also signifies Lesaffre's entry into the world of Synthetic Biology, considered to be the major biotechnological opportunity of this decade.

*"This kind of partnership exemplifies an innovative way that industry can support and foster progress in Biotechnology. Through collaboration with scientists and entrepreneurs, we will be able to find new solutions, which will be beneficial for the future, especially in health or in environment protection",* says Antoine Baule, Chief Executive Officer of Lesaffre.

### An exclusive technology

Recombia Biosciences was founded by three Stanford University researchers in 2019 as a spin-off from the prestigious Stanford Genome Technology Center (SGTC). Recombia's technologies are based upon techniques that increase the efficiency of genome editing and enable engineering of yeast at very high throughput. The strategic collaboration with Lesaffre aims to advance Recombia's proprietary gene editing technologies to identify new yeast strains, discovery novel yeast physiology of industrial relevance and optimize the production of biosourced ingredients and biofuels.

*"We are excited to be working with Lesaffre on moving our gene editing programs forward," says Dr Justin Smith, CEO of Recombia. "We see tremendous potential to leverage our expertise in genome editing and synthetic biology to develop new and innovative fermentation solutions and products."*

Recombia is exclusively licensing four genome engineering technologies from Stanford University for their work.

*"While precision genome editing has certainly advanced recently, there are still challenges, especially in making many genetic changes in parallel" said Dr. Bob St.Onge, COO and co-founder of Recombia Biosciences. "Recombia's technologies enable industrial yeast strain engineering by dramatically increasing the efficiency of high-throughput genome editing."*

St.Onge and Smith co-founded the company with Professor Lars Steinmetz. The team has had a long working relationship at the Stanford Genome Technology Center (SGTC).

*"I am very excited to see the technologies we developed in academia applied in the industrial sector" said Steinmetz. "The Genome Technology Center has a long history of genomics technology development. I'm confident Recombia will continue in the tradition of the other successful companies that have spun out of the SGTC."*


*"The technology has broad utility and can be readily applied also to the development of non-genetically modified organisms", says Carmen Arruda, Lesaffre R&I Manager. "With Recombia, Lesaffre can now explore a larger space of metabolic engineering hypotheses, develop prototype organisms at a faster pace, accelerate the design of appropriate selections and screenings of strains generated by classical breeding methods. We are excited to see what the future holds"*

### **Working together to better nourish and protect the planet**

As a global key player in the field of fermentation, Lesaffre is committed to continuing its investments in research and development to contribute to a safer, healthier and more natural world by developing the potential of micro-organisms, such as yeasts or beneficial bacteria.



*High-throughput genetics at Recombia Biosciences*



*Innovative technologies to screen Yeast biodiversity*

#### **ABOUT RECOMBIA BIOSCIENCES, INC**

Recombia was founded in 2019 as a spin-out of the Stanford Genome Technology Center. The company is based on technologies for enhanced high throughput genome editing and synthetic biology and will use these technologies to discover ways in which industrial strains of yeast can be improved for manufacturing different products. Recombia is located on the western shore of San Francisco Bay, a few miles south of the city of San Francisco and in the heart of the area's biotechnology hub.

More information on <https://www.recombia.com>

#### **ABOUT LESAFFRE**

A key global player in fermentation for more than a century, Lesaffre, with a 2,2 billion Euro turnover, and established on all continents, counts 10,700 employees and more than 70 nationalities. On the strength of this experience and diversity, we work with customers, partners and researchers to find ever more relevant answers to the needs of food, health, naturalness and respect for our environment. Thus, every day, we explore and reveal the infinite potential of microorganisms.

To nourish 10 billion people, in a healthy way, in 2050 by making the most of our planet's resources is a major and unprecedented issue. We believe that fermentation is one of the most promising answers to this challenge.

**Lesaffre - Working together to better nourish and protect the planet**

More information on [www.lesaffre.com](http://www.lesaffre.com)

Join us in conversation on [LinkedIn](#) and on [Twitter](#)